Filtered By:
Procedure: Heart Valve Surgery
Countries: Japan Health
This page shows you your search results in order of date.
Order by Relevance | Date
Total 28 results found since Jan 2013.
Edoxaban vs. Vitamin K Antagonist for Atrial Fibrillation After Transcatheter Aortic Valve Replacement in Japanese Patients - A Subanalysis of the ENVISAGE-TAVI AF Trial
CONCLUSIONS: In Japanese patients with AF after successful TAVR, edoxaban and VKA treatment have similar safety and efficacy profiles.PMID:35965066 | DOI:10.1253/circj.CJ-22-0093
Source: Circulation Journal - August 14, 2022 Category: Cardiology Authors: Yusuke Watanabe Kentaro Hayashida Masanori Yamamoto Futoshi Yamanaka Kazumasa Yamasaki Toru Naganuma Yohei Ohno Masahiro Yamawaki Nobuyuki Morioka Kazuki Mizutani Norio Tada Hiroshi Ueno Hidetaka Nishina Masaki Izumo Yoshifumi Nakajima Kenji Ando Kensuke Source Type: research
FDA Approves Two New Indications for XARELTO ® (rivaroxaban) to Help Prevent and Treat Blood Clots in Pediatric Patients
RARITAN, NJ, Dec. 20, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that the U.S. Food and Drug Administration (FDA) has approved two pediatric indications for XARELTO® (rivaroxaban): the treatment of venous thromboembolism (VTE, or blood clots) and reduction in the risk of recurrent VTE in patients from birth to less than 18 years after at least five days of initial parenteral (injected or intravenous) anticoagulant treatment; and thromboprophylaxis (prevention of blood clots and blood-clot related events) in children aged two years and older with congenital heart disease who have...
Source: Johnson and Johnson - December 21, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news
Impact of mitral versus aortic bioprosthetic valve position on thromboembolism and bleeding risk in patients with atrial fibrillation
CONCLUSIONS: In Japanese patients with AF and bioprosthetic valves, thromboembolic risk does not differ on the basis of valve position. Bleeding risk is higher in patients with MV bioprostheses, although valve position itself might not be an independent predictor for bleeding.PMID:34716054 | DOI:10.1016/j.jjcc.2021.10.002
Source: Journal of Cardiology - October 30, 2021 Category: Cardiology Authors: Yuki Obayashi Makoto Miyake Masashi Amano Takeshi Kitai Misa Takegami Kunihiro Nishimura Toshihiro Tamura Yutaka Furukawa Chisato Izumi Source Type: research
One-year outcomes of the pivotal clinical trial of a balloon-expandable transcatheter aortic valve implantation in Japanese dialysis patients
CONCLUSIONS: TAVR using SAPIEN 3 is safe and effective for the treatment of Japanese dialysis patients with symptomatic severe aortic valve stenosis.PMID:34348863 | DOI:10.1016/j.jjcc.2021.07.006
Source: Journal of Cardiology - August 5, 2021 Category: Cardiology Authors: Koichi Maeda Toru Kuratani Isamu Mizote Kentaro Hayashida Hikaru Tsuruta Tatsuo Takahashi Keiichi Fukuda Hideyuki Shimizu Yasushi Sakata Yoshiki Sawa Source Type: research
